MARKET

ARTL

ARTL

Artelo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8600
+0.0100
+1.18%
Closed 16:00 09/21 EDT
OPEN
0.8682
PREV CLOSE
0.8500
HIGH
0.8682
LOW
0.8123
VOLUME
59.02K
TURNOVER
--
52 WEEK HIGH
4.423
52 WEEK LOW
0.6100
MARKET CAP
3.87M
P/E (TTM)
-0.6393
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference
GlobeNewswire · 09/11 14:00
Artelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit
LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer and Andy Yates, PhD, Interim Chief
GlobeNewswire · 09/10 13:15
Artelo Biosciences (ARTL) Investor Presentation - Slideshow
The following slide deck was published by Artelo Biosciences, Inc. in conjunction with this event.
Seekingalpha · 09/03 17:29
LD Micro: 360 Companies - Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
ACCESSWIRE · 08/31 23:12
OpGen leads healthcare gainers; iBio and Can-Fite BioPharma among losers
Gainers: OpGen (OPGN) +28%. Kazia Therapeutics (KZIA) +14%. CureVac (CVAC) +14%. Ontrak (OTRK) +13%. Zosano Pharma (ZSAN) +12%.Losers: Teligent (TLGT) -18%. iBio (IBIO) -13%. Artelo Biosciences (ARTL) -11%. Can-Fite BioPharma (CANF) -9%. Allied Healthcare Products (AHPI)
Seekingalpha · 08/20 15:02
The Week In Cannabis: Stocks On The Rise, Earnings, Big Cannabis Sales, Moves In Argentina
Cannabis stocks were back in the green this week, as earnings season kicked off.
Benzinga · 07/17 20:43
Artelo Biosciences EPS beats by $0.09
Artelo Biosciences (NASDAQ:ARTL): Q3 GAAP EPS of -$0.27 beats by $0.09. Cash balance of ~$1.28M. Press Release
seekingalpha · 07/14 18:32
Artelo Biosciences Reports Q3 EPS $(0.27) Down From $(0.17) Q3 2019
Benzinga · 07/14 13:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARTL stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 4
Institutional Holdings: 14.94K
% Owned: 0.33%
Shares Outstanding: 4.50M
TypeInstitutionsShares
Increased
1
1
New
2
-99
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ARTL stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARTL
Artelo Biosciences, Inc. is a biopharmaceutical company. The Company is focused on licensing, developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). It develops and commercializes ethical pharmaceutical products that provide physicians access to the therapeutic potential of cannabinoid therapeutics and other modulators of the ECS for their patients. Its pipeline includes ART12.11, ART26.12 and ART27.13. The Company is developing ART12.11 for targeting the development in Inflammatory Bowel Disease (IBD), stroke and rare/orphan diseases. ART26.12 is its endocannabinoid transport protein (FABP5) inhibitor for treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain. ART27.13 is being developed for cancer. The Company also intends to develop a formulation suitable for treatment of anorexia/weight loss associated with cancer (cachexia).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Artelo Biosciences Inc stock information, including NASDAQ:ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.